Combined trimethoprim and caspofungin treatment for severe pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia

被引：30

作者：

Beltz, K.

Kramm, C. M.

Laws, H. -J.

Schroten, H.

Wessalowski, R.

Goebel, U.

机构：

[1] Univ Hosp Dusseldorf, Dept Pediat Oncol Hematol & Immunol, Dusseldorf, Germany

[2] Univ Hosp Dusseldorf, Dept Gen Pediat, Ctr Pediat & Adolescent Med, Dusseldorf, Germany

来源：

KLINISCHE PADIATRIE | 2006年 / 218卷 / 03期

关键词：

pneumocystis jiroveci pneumonia; acute respiratory failure; immunosuppression;

D O I：

10.1055/s-2006-933433

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Caspofungin was used for the first time with trimethoprim/sulfamethoxazole (TMP/SMX) for treatment of high risk Pneumocystis jiroveci pneumonia (PCP) in a pediatric immunocompromised patient. Despite the need for mechanical ventilation, the pediatric patient with relapsed acute lymphoblastic leukemia improved within nine days of treatment and showed no major side effects. The apparent relative lack of toxicity and of pharmacokinetic drug interactions makes caspofungin an attractive agent.

引用

收藏

页码：177 / 179

页数：3

相关论文

共 12 条

[1]

ANNALORO C, 2005, EUR J CLIN MICROBIOL, V20, P1

[2] Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia [J].

Eckert, C ;

Biondi, A ;

Seeger, K ;

Cazzaniga, G ;

Hartmann, R ;

Beyermann, B ;

Pogodda, M ;

Proba, J ;

Henze, G .

LANCET, 2001, 358 (9289) :1239-1241

[3]

EWIG S, 1995, EUR RESPIR J, V8, P1548

[4] Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients [J].

Groll, AH ;

Ritter, J .

KLINISCHE PADIATRIE, 2005, 217 :S37-S66

[5] New antifungal drugs and the pediatric cancer patient: Current status of clinical development [J].

Groll, AH ;

Lehrnbecher, T .

KLINISCHE PADIATRIE, 2005, 217 (03) :158-168

[6] Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections [J].

Groll, AH ;

Walsh, TJ .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (08) :1545-1558

[7] Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92 [J].

Harms, DO ;

Janka-Schaub, GE .

LEUKEMIA, 2000, 14 (12) :2234-2239

[8] Pneumocystis carinii pneumonia in patients with malignant haematological diseases:: 10 years' experience of infection in GIMEMA centres [J].

Pagano, L ;

Fianchi, L ;

Mele, L ;

Girmenia, C ;

Offidani, M ;

Ricci, P ;

Mitra, ME ;

Picardi, M ;

Caramatti, C ;

Piccaluga, P ;

Nosari, A ;

Buelli, M ;

Allione, B ;

Cortelezzi, A ;

Fabbiano, F ;

Milone, G ;

Invernizzi, R ;

Martino, B ;

Masini, L ;

Todeschini, G ;

Cappucci, MA ;

Russo, D ;

Corvatta, L ;

Martino, P ;

Del Favero, A .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (02) :379-386

[9] Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii [J].

Powles, MA ;

Liberator, P ;

Anderson, J ;

Karkhanis, Y ;

Dropinski, JF ;

Bouffard, FA ;

Balkovec, JM ;

Fujioka, H ;

Aikawa, M ;

McFadden, D ;

Schmatz, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :1985-1989

[10] Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients [J].

Roblot, F ;

Godet, C ;

Le Moal, G ;

Garo, B ;

Souala, MF ;

Dary, M ;

de Gentile, L ;

Gandji, JA ;

Guimard, Y ;

Lacroix, C ;

Roblot, P ;

Becq-Giraudon, B .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (07) :523-531